B-ALL GPR65 expression influences susceptibility to CAR-T therapy through a VEGF and macrophage-dependent mechanism
RNA-seq (gene expression) · mouse · 22 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 22 samples: 5 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- GPR65 Inactivation in Tumor Cells Drives Antigen-Independent CAR T-cell Resistance via Macrophage RemodelingCancer discovery · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE266166_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1106037 and SRA study SRP446341. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 15 samples.
How we read this: 5 replicated groups read from 22 sample titles; they account for 15 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7517101 C8untreated
- GSM7517102 C8GPR65KOuntreated
- GSM7517103 C8CART_tumor_CART
- GSM7517104 C8GPR65KOCART_tumor_CART
- GSM7517105 C8CART_host
- GSM7517106 C8GPR65KOCART_host
- GSM8241719 CART_rep1 CART
- GSM8241720 CART_rep2 CART
- GSM8241721 CART_rep3 CART
- GSM8241722 CART_CR_rep1 CART_CR
- GSM8241723 CART_CR_rep2 CART_CR
- GSM8241724 CART_CR_rep3 CART_CR
- GSM8241725 CART_GPR65KO_rep1 CART_GPR65KO
- GSM8241726 CART_GPR65KO_rep2 CART_GPR65KO
- GSM8241727 CART_GPR65KO_rep3 CART_GPR65KO
- GSM8241728 S1 to S14
- GSM8242956 PR_rep1 PR
- GSM8242957 PR_rep2 PR
- GSM8242958 PR_rep3 PR
- GSM8242959 CR_rep1 CR
- GSM8242960 CR_rep2 CR
- GSM8242961 CR_rep3 CR
- GSE266164 B-ALL GPR65 expression influences susceptibility to CAR-T therapy through a VEGF and macrophage-dependent mechanism [bulk RNA-Seq] 9 samples shares b-all, gpr65, car-t, vegf, macrophage-dependent, susceptibility, influences, therapy
- GSE236031 B-ALL GPR65 expression influences susceptibility to CAR-T therapy through a VEGF and macrophage-dependent mechanism [scRNA-Seq] 6 samples shares b-all, gpr65, car-t, vegf, macrophage-dependent, susceptibility, influences, therapy
- GSE266240 B-ALL GPR65 expression influences susceptibility to CAR-T therapy through a VEGF and macrophage-dependent mechanism [RNA-Seq] 6 samples shares b-all, gpr65, car-t, vegf, macrophage-dependent, susceptibility, influences, therapy
- GSE266165 B-ALL GPR65 expression influences susceptibility to CAR-T therapy through a VEGF and macrophage-dependent mechanism [enrichement scRNA-Seq] 1 samples shares b-all, gpr65, car-t, vegf, macrophage-dependent, susceptibility, influences, therapy
- GSE303385 Temporal mapping of the anti-tumor effects of nanobody-based MSLN.CAR-T cell therapy in metastatic solid tumors [total RNA-Seq] 34 samples shares car-t, therapy
- GSE303224 Temporal mapping of the anti-tumor effects of nanobody-based MSLN.CAR-T cell therapy in metastatic solid tumors [scRNA-Seq] 32 samples shares car-t, therapy
- GSE287413 CAR-T cell therapy for chronic kidney disease 12 samples shares car-t, therapy
- GSE326798 CDK4/6 Inhibition Enhances CAR-T Cell Therapy in Solid Tumors 12 samples shares car-t, therapy
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.